Dr. Htet is a board certified physician in Emergency Medicine and Critical Care Medicine. She earned her undergraduate degree in Biochemistry and Neuroscience at University of California Los Angeles (UCLA) and her masters degree in Physiological Science at UCLA. She received her M.D. degree from the University of Wisconsin School of Medicine and Public Health. During medical school, she was a part of leadership team for free clinics in the area, and performed research in the field of neuroimaging concurrent with her interest in undergraduate and graduate studies. She did her residency in Emergency Medicine at Advocate Christ Medical Center in Oak Lawn, near Chicago. She was involved in national emergency medicine organizations and mentor groups. She finished her fellowship training in Critical Care Medicine at Stanford and worked in intensive care units at Stanford, Veteran Affairs Hospital in Palo Alto, and Santa Clara Valley hospital. She practices in the Emergency Dept and ICU at Stanford. Her career interests involve medical education, critical care Echo, palliative care, diversity advocacy, hemodynamic monitoring and neurocritical care.
- Critical Care
- Medical Education
- Patient education
- Palliative Care
- Emergency Medicine
Clinical Assistant Professor, Emergency Medicine
Honors & Awards
Emergency Medicine Foundation Grant, Advocate Christ Medical Center (2015)
Emergency Medicine Foundation Grant, Advocate Christ Medical Center (2014)
Don Bruechert Medical Scholarship, University of Wisconsin School of Medicine and Public Health (2012)
Student Leadership and Service Book Award, University of Wisconsin School of Medicine and Public Health (2011)
Shapiro Research Award, University of Wisconsin School of Medicine and Public Health (2010)
Boards, Advisory Committees, Professional Organizations
Member, Society of Academic Emergency Medicine, Critical Care Group and ADIEM (Academy for Diversity & Inclusion in Emergency Medicine) (2022 - Present)
Member, Society of Critical Care Medicine, Ultrasound Committee, Emergency Medicine (2018 - Present)
Member, American Thoracic Society (2017 - Present)
Member, American College of Emergency Physicians (2013 - Present)
Board Certification: American Board of Internal Medicine, Critical Care Medicine (2019)
Fellowship: Stanford University Pulmonary and Critical Care Fellowship (2018) CA
Board Certification: American Board of Emergency Medicine, Emergency Medicine (2017)
Residency: Advocate Christ Medical Center (2016) IL
Medical Education: University of Wisconsin Madison Office of the Registrar (2013) WI
M.D., University of Wisconsin School of Medicine and Public Health, Medicine (2013)
Residency, Advocate Christ Medical Center, Emergency Medicine (2016)
Fellowship, Stanford Medicine Critical Care Fellowship, Critical Care Medicine (2018)
Community and International Work
MEDiC (Student-Run Free Medical Clinics), Madison
Opportunities for Student Involvement
Current Research and Scholarly Interests
Genetic phenotyping of patients in septic shock
Graduate and Fellowship Programs
Critical Care Medicine (Fellowship Program)
- Advanced Critical Care Ultrasound: Axillary Arterial Line- Oft Forgotten EMRA. 2022
Protocolized use of Factor Eight Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin induced coagulopathy
AMERICAN JOURNAL OF EMERGENCY MEDICINE
2020; 38 (3): 539-544
Coagulopathy due to warfarin in patients with major bleeding was traditionally reversed with fresh frozen plasma and intravenous (IV) vitamin K, but prothrombin complex concentrates (PCC) are increasingly used in the treatment of these patients. Factor Eight Inhibitor Bypassing Activity (FEIBA) is an activated four-factor PCC most commonly used in patients with hemophilia. We aimed to evaluate the efficacy and safety of FEIBA and IV vitamin K for the reversal of warfarin-associated coagulopathy in patients with major bleeding, by measuring the percentage of patients who achieved target INR ≤ 1.5 and the incidence of thrombotic adverse events (TAE).In this prospective observational study, we enrolled patients presenting to the Emergency Department (ED) with warfarin associated coagulopathy (INR > 1.5) and major bleeding. Patients received FEIBA using an INR based dosing strategy and IV vitamin K.In 43 patients, median initial INR was 4.0 (2.7, 7.3 interquartile range (IQR)). Median time to result the second INR was 45 min (38, 55 IQR) and the median INR was 1.4 (1.3, 1.6 IQR). Out of the 43 patients, 93% achieved the target INR of ≤1.5. In-hospital mortality was 40% (17 patients). There were 11 TAEs in 6 patients (14%); 4 events in 2 patients (5%) were attributed to FEIBA.A protocolized use of FEIBA and IV vitamin K resulted in the efficacious reversal of warfarin-induced coagulopathy in patients with major bleeding. TAEs occurred in 14% of patients and were attributed to FEIBA in 5% of patients.
View details for DOI 10.1016/j.ajem.2019.05.047
View details for Web of Science ID 000539260200016
View details for PubMedID 31176578
Critical Care Education Day: A Novel, Multidisciplinary, and Interactive Critical Care Education Session for Emergency Medicine Residents.
2020; 12 (1): e6785
Critical care medicine (CCM) is central to emergency medicine (EM) resident education. We feel that the traditional lecture format is not the ideal way to teach EM critical care, which requires integration and prioritization of diagnostic workup and team-based resuscitation under time pressure. We describe a novel critical care education day where an interactive, practical, and multidisciplinary critical care educational experience was provided for EM residents using case-based small-group sessions and fast-paced simulation.
View details for DOI 10.7759/cureus.6785
View details for PubMedID 32140345
View details for PubMedCentralID PMC7045984
Acute Respiratory Distress Syndrome: Etiology, Pathogenesis, and Summary on Management.
Journal of intensive care medicine
The acute respiratory distress syndrome (ARDS) has multiple causes and is characterized by acute lung inflammation and increased pulmonary vascular permeability, leading to hypoxemic respiratory failure and bilateral pulmonary radiographic opacities. The acute respiratory distress syndrome is associated with substantial morbidity and mortality, and effective treatment strategies are limited. This review presents the current state of the literature regarding the etiology, pathogenesis, and management strategies for ARDS.
View details for DOI 10.1177/0885066619855021
View details for PubMedID 31208266
- SEVERE INTRAVASCULAR HEMOLYSIS WITH CLOSTRIDIUM PERFRINGENS BACTEREMIA LIPPINCOTT WILLIAMS & WILKINS. 2018: 295
Needle-guided ultrasound technique for axillary artery catheter placement in critically ill patients: A case series and technique description.
Journal of critical care
2017; 41: 194-197
Axillary arterial cannulation for blood pressure monitoring has been reported in adults since 1973. Reported failure rates using palpation landmarks are high. This report describes a needle-guided ultrasound technique for axillary arterial line placement in critically ill patients.A retrospective review of all patients requiring axillary arterial cannulation attempts with ultrasound-assisted needle guidance for hemodynamic monitoring was performed from July 2010 to June 2016 at a single institution.One hundred fifty nine (159) cannulation attempts were performed in 155 patients. The overall success rate was 97%, with a first pass success rate of 84%. Inexperienced operators performed 49% of procedures under direct faculty supervision, and had a 99% success rate, which was not different from experienced operators. Almost 20% of patients had moderate-to-severe coagulopathy (platelets<50k/uL, INR>2.0 or PTT>60s). Complications reported included the following: nonfunctioning of catheter (6%) and hematoma (6%). Ischemia was noted in 2 patients (1%), but only one was attributed to the arterial catheter.Use of the needle-guided ultrasound assisted approach for axillary arterial line placement is easily teachable and can be used to promote safe and successful placement of axillary arterial lines for novice learners.
View details for DOI 10.1016/j.jcrc.2017.05.026
View details for PubMedID 28577475
Biodistribution and predictive value of (IF)-I-18-fluorocyclophosphamide in mice bearing human breast cancer xenografts
JOURNAL OF NUCLEAR MEDICINE
2007; 48 (12): 2021-2027
In mice bearing human breast cancer xenografts, we examined the biodistribution of (18)F-fluorocyclophosphamide ((18)F-F-CP) to evaluate its potential as a noninvasive prognostic tool for predicting the resistance of tumors to cyclophosphamide therapy.(18)F-F-CP was synthesized as we recently described, and PET data were acquired after administration of (18)F-F-CP in mice bearing human breast cancer xenografts (MCF-7 cells). Tracer biodistribution in reconstructed images was quantified by region-of-interest analysis. Distribution was also assessed by harvesting dissected organs, tumors, and blood, determining (18)F content in each tissue with a gamma-well counter. The mice were subsequently treated with cyclophosphamide, and tumor size was monitored for at least 3 wk after chemotherapy administration.The distribution of harvested activity correlated strongly with distribution observed in PET images. Target organs were related to routes of metabolism and excretion. (18)F-F-CP uptake was highest in kidneys, lowest in brain, and intermediate in tumors, as determined by both image-based and tissue-based measurements. (18)F-F-CP uptake was not inhibited by coadministration of an approximately x700 concentration of unlabeled cyclophosphamide. PET measures of (18)F-F-CP uptake in tumor predicted the magnitude of the response to subsequent administration of cyclophosphamide.Noninvasive assessment of (18)F-F-CP uptake using PET may potentially be helpful for predicting the response of breast tumors to cyclophosphamide before therapy begins.
View details for DOI 10.2967/jnumed.107.045716
View details for Web of Science ID 000252895100020
View details for PubMedID 18006620